文献速递核素与放射性配体治疗甲状腺核医学

胆囊收缩素2受体激动剂177Lu-PP-F11N用于甲状腺髓样癌核素治疗的Lumed 0a期研究

Cholecystokinin 2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study.
PubMed 文献 · J Nucl Med · 2019-09-13

该0a期研究在6例晚期甲状腺髓样癌患者中评估了新型微小胃泌素类似物177Lu-PP-F11N的剂量学与安全性。患者随机交叉接受约1 GBq(约80 μg)的177Lu-PP-F11N,分别联合或不联合琥珀酰明胶。结果显示药物在肿瘤中特异性聚集,肿瘤吸收剂量中位数为0.88 Gy/GBq,肾脏和骨髓剂量低,胃可能是剂量限制器官,不良反应均为1级且自限。

要点

  • 177Lu-PP-F11N在甲状腺髓样癌肿瘤中特异性聚集,中位吸收剂量0.88 Gy/GBq。
  • 肾脏和骨髓辐射剂量低,肿瘤/肾脏剂量比中位数11.6(无SG)与13.0(联合SG)无显著差异(P=1.0)。
  • 胃可能是剂量限制器官,肿瘤/胃剂量比中位数3.34。

核心结论

  • 177Lu-PP-F11N以足以用于治疗目的的剂量特异性聚集于甲状腺髓样癌,肾脏和骨髓辐射剂量低,生物分布有前景,胃最可能是剂量限制器官。

研究设计与样本

  • 6例连续患者接受2次约1 GBq(约80 μg)177Lu-PP-F11N注射,联合或不联合琥珀酰明胶溶液,随机交叉序列,评估生物分布、药代动力学及肿瘤和器官剂量学,并随访12周评估安全性。

主要发现

  • 所有患者肿瘤组织、胃和肾脏均可见177Lu-PP-F11N聚集,共13个肿瘤可进行剂量学评估。
  • 肿瘤、胃、肾脏和骨髓的中位吸收剂量分别为0.88(IQR 0.85-1.04)、0.42(IQR 0.25-1.01)、0.11(IQR 0.07-0.13)和0.028(IQR 0.026-0.034)Gy/GBq。
  • 无SG和联合SG时肿瘤/肾脏剂量比中位数分别为11.6(IQR 8.11-14.4)和13.0(IQR 10.2-18.6),差异无统计学意义(P=1.0)。
  • 肿瘤/胃剂量比中位数为3.34(IQR 1.14-4.70)。
  • 不良反应主要为低血压、潮红和低钾血症,均自限且不超过1级。

关键数值与推荐

  • 肿瘤中位吸收剂量0.88 Gy/GBq(IQR 0.85-1.04)。
  • 肾脏中位吸收剂量0.11 Gy/GBq(IQR 0.07-0.13),骨髓0.028 Gy/GBq(IQR 0.026-0.034)。
  • 肿瘤/肾脏剂量比中位数无SG为11.6(IQR 8.11-14.4),联合SG为13.0(IQR 10.2-18.6),P=1.0。
  • 肿瘤/胃剂量比中位数3.34(IQR 1.14-4.70)。

临床怎么用

  • 177Lu-PP-F11N有望用于甲状腺髓样癌的核素治疗,需进一步临床研究评估最大耐受剂量和疗效。

局限性

  • 样本量仅6例,为0a期研究,需进一步临床研究评估最大耐受剂量和疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment of patients with advanced medullary thyroid carcinoma (MTC) is still a challenge. For more than 2 decades, it has been known that the cholecystokinin 2 receptor is a promising target for the treatment of MTC with radiolabeled minigastrin analogs. Unfortunately, kidney toxicity has precluded their therapeutic application so far. In 6 consecutive patients, we evaluated with advanced 3-dimensional dosimetry whether improved minigastrin analog 177Lu-DOTA-(d-Glu)6-Ala-Tyr-Gly-Trp-Nle-Asp-PheNH2 (177Lu-PP-F11N) is a suitable agent for the treatment of MTC. Methods: Patients received 2 injections of about 1 GBq (∼80 μg) of 177Lu-PP-F11N with and without a solution of succinylated gelatin (SG, a plasma expander used for nephroprotection) in a random crossover sequence to evaluate biodistribution, pharmacokinetics, and tumor and organ dosimetry. An electrocardiogram was obtained and blood count and blood chemistry were measured up to 12 wk after the administration of 177Lu-PP-F11N to assess safety. Results: In all patients, 177Lu-PP-F11N accumulation was visible in tumor tissue, stomach, and kidneys. Altogether, 13 tumors were eligible for dosimetry. The median absorbed doses for tumors, stomach, kidneys, and bone marrow were 0.88 (interquartile range [IQR]: 0.85-1.04), 0.42 (IQR: 0.25-1.01), 0.11 (IQR: 0.07-0.13), and 0.028 (IQR: 0.026-0.034) Gy/GBq, respectively. These doses resulted in median tumor-to-kidney dose ratios of 11.6 (IQR: 8.11-14.4) without SG and 13.0 (IQR: 10.2-18.6) with SG; these values were not significantly different (P = 1.0). The median tumor-to-stomach dose ratio was 3.34 (IQR: 1.14-4.70). Adverse reactions (mainly hypotension, flushing, and hypokalemia) were self-limiting and not higher than grade 1. Conclusion:177Lu-PP-F11N accumulates specifically in MTC at a dose that is sufficient for a therapeutic approach. With a low kidney and bone marrow radiation dose, 177Lu-PP-F11N shows a promising biodistribution. The dose-limiting organ is most likely the stomach. Further clinical studies are necessary to evaluate the maximum tolerated dose and the efficacy of 177Lu-PP-F11N.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Rottenburger C, Nicolas GP, McDougall L, et al. Cholecystokinin 2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study. J Nucl Med. 2019. PMID: 31519804. doi:10.2967/jnumed.119.233031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。